anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present disclosure provides methods and compositions for delivering RNA constructs to cells for functional expression and/or activity. In some aspects, the present disclosure provides a composition comprising a multifunctional nanoparticle. The multifunctional nanoparticle comprises a core functionalized with at least one RNA molecule, at least one Cell Penetrating Peptide (CPP) and at least one positively charged moiety, each of which is independently attached to the core, optionally with a linker moiety. In some embodiments, the RNA molecule is an uncapped mRNA molecule that is attached at its 5&#39; end to a linker moiety that is attached to the core. The multifunctional nanoparticle is substantially uncharged, negatively charged, or positively charged. The multifunctional nanoparticles are useful in methods of delivering and expressing a polypeptide of interest in a cell for a variety of purposes, including vaccination, cancer treatment, telomere extension, modification of cell signaling pathways, and the like.
1,179,938. Medicinal tablets. MERCK &amp; CO. Inc. 20 Nov., 1967 [23 Nov., 1966], No. 52706/67. Heading A5B. A sustained release tablet, which comprises a core composed of medicament dispersed in a wax or wax-like material and surrounded by a coating (which may also contain a medicament) which preserves its shape at the temperature at which the wax melts, is made by forming the core by compression of a mixture of wax and medicament, applying the coating by conventional methods, heating the tablet to ensure melting of the wax and cooling to room temperature. Suitable wax materials are hardened animal, vegetable and mineral oils, higher fatty alcohols and acids, beeswax, glycerol monostearate and polyethylene oxide. Suitable coating materials are methyl- and ethyl-cellulose, cellulose acetate, cellulose acetate phthalate and hydroxypropyl cellulose. Examples relate to tablets containing KCl, amitriptylene and chlorothiazide. An additional outer coating, e.g. of sugar, may be applied to the tablets.
PURPOSE:To obtain a Chinese herb extract having excellent disintegrability, by adding and reacting amylase to the extracted or concentrated liquid of Chinese herb, drying and pulverizing the reaction product and optional mixing with an excipient such as sugar, cellulose, etc. CONSTITUTION:Chinese herb drug [e.g. KAKKON-TO (decocted root of Pueraria lobata), ANCHU-SAN (mixed powder of the root of Glycyrrhiza glaba, rhizome of Zingiber officinale, etc.), KOSAIKO-TO, etc.] is extracted with a solvent (e.g. water, aqueous solution of ethanol of &lt;=25% concentration), and the extracted liquid or its concentrate is reacted with amylase. The amount of amylase is preferably 0.005-0.1wt% based on the starch in the liquid. The reaction liquid is dried and the obtained powder is used as it is or mixed with an excipient (e.g. sugar, starch, dextrin, etc.) to obtain a Chinese herb extract having various forms (e.g. tablet, capsule, powder, etc.). The obtained herb extract has excellent disintegrability.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an oily cosmetic composition excellent in suspending ability.  &lt;P&gt;SOLUTION: This oily cosmetic composition having suspending ability acts as a lubricating and moistening agent and a protective agent for skin, mucous membrane and hair and further acts as a base for decorative or aromatic cosmetic. The composition exhibits an oil-gel form and may be transparent, translucent or opaque. The composition exhibits excellent suspending ability and is readily applicable to the skin and exhibits good smoothness of the skin and has comfortable touch feeling such as silky touch feeling after coating. The composition has a characteristic in combination of a styrene-ethylene/propylene copolymer with silica in an oily base. The composition may contain particles in suspension so as to have decorative and/or functionality-imparting characteristics.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE: An external use skin composition is provided to have a safe skin whitening effect without skin irritation using tengeretin contained in a citrus peel extract and epigallocatechin gallate (EGCG) contained in a green tea extract. CONSTITUTION: An external use skin composition contains tangeretin and EGCG. Tangeretin is contained in a citrus peel extract. EGCG is contained in a green tea extract. The composition contains 0.001-10 wt% of a citrus peel extract and 0.001-99.9 wt% of the green tea extract. [Reference numerals] (AA) p-value of each value treated with tangeretin &lt; 0.05
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new melanoma treatment.  &lt;P&gt;SOLUTION: The composition comprises a peptide which stimulates an antibody response to a high molecular weight melanoma-associated antigen (HMW-MAA). The method for stimulating an immune response to a HMW-MAA comprises using the peptide. The peptide is designed from a structure between a HMW-MAA and mouse-anti-idiotypic monoclonal antibody MK2-23 and identification of domain of amino acid sequence homology. The method comprises a step for administering one or more kinds of the peptides in an amount effective for inducing an immune response to a HMW-MAA to an individual.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
Unfilled prescriptions are submitted to a registry comprising pre-qualified pharmacies for a &#39;reverse auction&#39; in which the pharmacies bid for the opportunity to fill the prescription. The pharmacies are allowed to bid based on price and/or offering ancillary services. The auction may also be used to bid on supplying specified pharmaceutical cognitive services. The method may also include obtaining cost comparisons with generic substitutes or similar alternative pharmaceutical products. The system may further comprise automatically requesting a review by the prescriber for a list of similar substitutes or prior-authorization for third- party payers. The winner of the reverse auction is selected by the customer.
1328854 Polymerizable dental materials MINNESOTA MINING &amp; MFG CO 2 Nov 1970 [3 Nov 1969] 52071/70 Addition to 1267448 Heading C3P  Mouldable dental restorative compositions having a moisture absorption, after hardening and exposure to moisture, of less than 1% by weight, comprise an inorganic particulate filler and a liquid binder capable of being polymerized in the presence of a free radical initiator, the binder comprising a monomeric polyacrylate or polymethacryate ester of an etherified diphenol which has been etherified at each phenolic hydroxyl group by a molecule of a diol or triol, the diphenol group comprising at least two aromatic nuclei joined directly through a single carbon-carbon bond or through a divalent linking group, and the polyester being substantially free from active hydrogen atoms and devoid of peroxides. A polymerization accelerator is preferably also included, e.g. an N,N-bis- (hydroxyalkyl) - p - toluidine or -3,5 - xylidene wherein the alkyl group has 2 to 6 carbon atoms. Suitable fillers include lithium aluminium silicates, hydroxy apatite, silica or siliceous materials, alumina or aluminoferrous materials, and glasses such as borosilicate glasses; the filler may be modified to promote adhesion by the binder, e.g. by a conventional vinyl silane treatment. Small amounts of pigment may be included in the filler for visual colour or fluorescent effect. The polymerizable ester is preferably one of the formula in which M is a methacryloyl or acryloyl group, D is C 2 -C 6  alkylene, X is the nucleus of a diphenol having at least two aromatic nuclei joined as described above and having from 12-24 carbon atoms, T is the nucleus of a triprimary triol and n is an integer. The compositions can be stored in two-component kit form with the ingredients of the composition being apportioned between the two components. In examples an adduct of glycidyl methacrylate and phenyl salicylate is used as a comonomer for the binder, and benzoyl peroxide is used as polymerization initiator.
PURPOSE:To obtain the title granules with lamellar crystals, excellent in the durability in the rumen and the dissolution absorbability in the abomasum and thereafter by coating a specific core granules with a mixture of 12-22C fatty acid, fatty acid ester, etc., and specific lamellar crystals. CONSTITUTION:The objective granules can be obtained by coating core granules containing non-fluid physiologically active substance(s) (e.g. saccharide, amino acid) with (A) a mixture comprising at least one kind of materials selected from 12-22C fatty acids or their esters, (hardened) animal or vegetable fatty oils &gt;=40 deg.C in melting point (e.g. palm oil, tallow, hardened caster oil) and wax &gt;=40 deg.C in melting point (e.g. beeswax) and (B) lamellar crystals 5-30mum in mean particle size poorly soluble in water in a neutral state but readily soluble in water in an acidic state (e.g. consisting of an amino acid such as isoleucine) at the weight ratio A/B=(3:2)-(1:3). In the present granules, the coating layers contain the lamellar crystals in a laminar fashion.
The disclosure relates to methods and systems of providing secure remote health data routing for diagnostics, treatment, monitoring, and/or other health data. The system may use an anonymized identification (ID) token that may protect privacy and ensure security. The ID token may be attached with additional data such as electronic medical record (EMR) data. As such, the system may digitize and securely transmit EMR data to appropriate constituents. The system may apply routing rules and routing tables to identify the appropriate constituents. The system may also route the EMR data for storage at a user&#39;s personal device, which may include a chip card or a user device. As such, the user&#39;s personal device may store an EMR based on the EMR data, including proof of health, such as vaccination, and other health data relating to the user.
PURPOSE:The titled external agent containing a specific anti-inflammatory steroid. CONSTITUTION:A percutaneous absorption type steroid external agent containing 0.1-5wt%, preferably 0.5-2.5wt%, anti-inflammatory steroid in which the OH group at the 21-position is substituted by a group expressed by the formula -OCO(R)nCOOH (R is -CH2-; n is an integer 0-7) or farnesyl group or a salt thereof. The agent is in the form of an acid (-COOH) under acidic conditions (3.5-6.5pH), and is easily passed through the skin, and becomes COO&lt;-&gt; at about 7.4pH under the skin to provides easy migration in the body. Examples of the above-mentioned anti-inflammatory steroid include prednisone, dexameth asone, betamethasone, etc. The dosage form includes ointment, cream or jelly. The agent is applicable to chronic articular rheumatism, arthritis accompanied by collagen disease, deformed arthrosis, gout, lumbago, frozen shoulder, etc.
1. A method of inhibiting colon cancer comprising administering to a mammal in need thereof an effective amount of a compound having the formula (I)   wherein R&lt;1&gt; and R&lt;3&gt; are independently hydrogen, -CH3,   or   wherein Ar is optionally substituted phenyl; R&lt;2&gt; is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof. 2. The method of claim 1 wherein said mammal is a human. 3. The method of claim 2 wherein said compound is the hydrochloride salt thereof. 4. The method of claim 3 wherein said compound is   or its hydrochloride salt.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain protein related to treatment and infection prevention of parasitic protozoiasis of erythrocyte of a protozoan belonging to the phylum Apicomplexian such as piroplasma protozoan, etc., and a DNA encoding the same and to provide a method for use thereof.  &lt;P&gt;SOLUTION: The protein comprises a DNA encoding piroplasma protozoan killing peptide protein of ixodid ticks. The vector comprises the DNA. The recombinant cell comprises the DNA. The piroplasma protozoan killing peptide protein, its synthetic peptide, the antibody recognizing the antigen and the antigen are obtained. The compound is obtained from the piroplasma protozoan killing peptide protein for exterminating piroplasma protozoa.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
PCT No. PCT/IT94/00124 Sec. 371 Date Mar. 23, 1995 Sec. 102(e) Date Mar. 23, 1995 PCT Filed Jul. 26, 1994 PCT Pub. No. WO95/03822 PCT Pub. Date Feb. 9, 1995Methods of using relaxin (RLX), a peptide hormone of the insulin family, which has been found to produce effects on the walls of blood vessels, on blood clotting and on blood lipids and electrolytes, per se, and through the stimulation of the synthesis and release of the two powerful substances: nitric oxide (NO) and atrial natriuretic peptide (ANP), are contemplated whereby RLX is administered to a patient for increasing blood flow, producing dilation of the arteries, influencing blood clotting and fibrinolysis, reducing blood lipids, inducing reduction of blood osmolarity and sodium concentration, and through NO for inhibiting release of histamine from mast cells. RLX is accordingly used as a therapeutic agent in methods for treating arteriosclerosis and vascular diseases, ischemia and thrombosis, hypertension and pregnancy&#39;s gestosis, and other diseases, or allergic and inflammatory disorders as dysfunctions in fluid and electrolyte balance.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide isolated protein complexes including a growth factor, e.g. insulin-like growth factor (IGF)-I, IGF-II, vascular endothelium growth factor (VEGF) or platelet-derived growth factor (PDGF), or at least domains of the growth factor that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin.  &lt;P&gt;SOLUTION: The protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence, in the case of a single synthetic protein. In particular forms, vitronectin or fibronectin sequences do not include at least any of a heparin-binding domain and a polyanionic domain. There are provided uses of these protein complexes for stimulating or inducing at least any of cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments, e.g. skin replacement and skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, there is provided inhibition of cancer cell metastasis, particularly in relation to breast cancer.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
FIELD: veterinary science, biotechnology. SUBSTANCE: vaccine contains aluminium hydroxide-adsorbed formalin-inactivated leucocidine- exotoxin, suspension of alive spores of anthracic vaccine strain 55-VNIIVV&amp;M at initial concentration being (5-5,5)•10 9  spores/cm 3  in physiological solution, 1 M-sodium metabisulfite solution and an oily adjuvant. Vaccine components are in a balanced ratio. Leucocidine-exotoxin is a highly purified protein at 18-20 kDa molecular weight. It is obtained out of production strain Fusobacterium necrophorum &#34;0-1&#34; VIEV. Associated vaccine is once injected for cattle, sheep, goats, pigs and Siberian stags intracutaneously with the help of a needle-free injector at 0.2-0.4 cm 3  volume. Associated vaccine against anthrax and necrobacteriosis is a highly efficient preparation to protect animals against these diseases, according to its immunogenicity it surpasses monovaccines that it contains. EFFECT: higher efficiency of prophylaxis. 2 ex
A method of displaying medical data, particularly data representative of the condition of patients suffering from chronic medical conditions such as asthma, diabetes and hypertension. The display consists of two graphical elements, one of which indicates the current value of a parameter indicative of the patient&#39;s condition, this being displayed against another graphical element which represents a model of normality for that patient. The graphical element indicating the current condition may be, for example, a needle, against a scale which is constructed according to the patient-specific model of normality. This is particularly advantageous in the case of displays which have a small display area, such as mobile telephones and PDAs. Other forms of display are disclosed, such as histograms with the display being dynamically colour-coded and auto-scaled, or displays including limits which may vary. Another form of display is also disclosed which illustrates administrations of a pharmacological agent and corresponding measurements of the patient&#39;s condition, with a visual link such as colour-coding linking the administration to the corresponding condition measurement. For example several days of insulin administration dosages may be displayed alongside several days of blood glucose measurements, with the administrations colour-coded to the corresponding blood glucose measurement, to assist the patient in determining whether the insulin administration is stably controlling their condition.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing hesperidin, which obtains hesperidin by an efficient process in a high yield.  &lt;P&gt;SOLUTION: The method for producing hesperidin includes bringing a citrus fruit into contact with a solvent composed of either or both of water and an organic solvent and performing an extraction treatment while irradiating with a microwave to give an extract (extraction treatment step) and removing a solid component contained in the extract to obtain a clear extract containing hesperidin (hesperidin acquisition step). The amount of the solvent used is 6-25 pts.mass based on 1 pt.mass of the citrus fruit and the extraction temperature is 110-190°C. The extract is cooled to give hesperidin crystal. The citrus fruit is pericarp of Citrus unshiu.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a pack sheet package of a pop-up type, the package being configured such that pack sheets of a large shape can be accommodated in layers in a container without being accommodated in a packaging bag to be disposed of, each pack sheet can easily be taken out even in a laminated form, and the pack sheets can easily be unfolded thereafter.  &lt;P&gt;SOLUTION: In the pack sheet package of the pop-up type, the uppermost pack sheet of a laminated has a pickup portions projecting upward from the leading edges of both upper ends of a face shape. The pack sheet is folded in a Z-shape widthwise and then folded lengthwise. The pack sheet is folded and placed in the position where the pickup portions of the folded pack sheet can be picked up from the extraction opening. The other pack sheets of the laminated are folded in the same manner as the uppermost pack sheet. The folded pack sheets are placed one on top of the other.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;amp;INPIT
A drum (1) which acts as roasting chamber is rotatably mounted by means of a hollow shaft (4) and set in rotation by a motor (11). The drum (1) can be heated by means of gas burners (15). Glass beads or similar particles which act as heat-transfer medium are introduced into the drum (1) via a ball valve (3). While the drum (1) is rotated, the heat transfer medium is brought to the desired temperature by means of the gas burners (15). Once the desired temperature is reached, the heat supply is interrupted, and the green coffee beans are added to the heated heat transfer medium. Coffee beans and heat transfer medium are brought into intimate contact by rotating the drum (1). When the roasting procedure is ended, the drum (1) is emptied, and the roasted coffee beans are separated from the heat transfer medium, which is recycled. The process allows organoleptic effects to be achieved, which improve the quality. However, in many cases, this improvement is linked to an increase in titratable acid. The improved quality is particularly obvious in the case of robusta coffee. &lt;IMAGE&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To solve a problem that a conventional dispensing waiting system can&#39;t provide correct waiting information to patients having different waiting times from each other due to dispensing complexity and the patients have no way else to do but know the completion from a pharmacy&#39;s display.  &lt;P&gt;SOLUTION: Status information of reception, dispensing start/end, and medicine by-hand delivery completion is sent with a patient ID in every classification of the dispensing complexity from a terminal on the Internet. An Internet server sends the status information in time sequence to the pharmacy&#39;s display or a patient&#39;s mobile phone in the every classification of the dispensing complexity. This informs the patient of the patient&#39;s dispensing status appropriately. If the patient sends a notice request for designating an order or a dispensing completion time from the mobile phone or the like, a calling mail corresponding to the request contents is sent to the patient.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Constructs including bars, capsules, beads, and sheets are configured with a radionuclide core that emits energetic particles activating a phosphorescent shell material surrounding the radionuclide core so that it emits light to administer light therapy or PDT. A biocompatible coating that is generally optically transparent encloses the radionuclide core and phosphorescent material to prevent a patient&#39;s body in which the constructs are disposed from being affected by any toxicity of the phosphorescent shell material. In a typical application of the constructs, a photoreactive agent is infused into the treatment site and selectively absorbed by abnormal tissue, for example, in a cancerous tumor. Light emitted by the phosphorescent material when activated by the energetic particles emitted from the radionuclide core administers photodynamic therapy, which destroys the abnormal tissue. Particularly, the beads, which are relatively small in size, can be targeted to abnormal tissue by providing a linking mechanism on the biocompatible coating so that the beads are coupled to antibodies found on the abnormal cells, but not on normal tissue. If a glass phosphor material that includes fused quartz or silica glass doped with metal ions is used for the phosphorescent shell material, the beads or other construct must be exposed to IR or other light, causing electrons that have been trapped inside the glass materials to combine with holes, emitting light of a shorter wavelength. The glass phosphor material is preferable, since it is substantially less toxic than other types of scintillators or phosphor materials.